Share on StockTwits

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) have received an average recommendation of “Hold” from the nine brokerages that are currently covering the stock, AmericanBankingNews.com reports. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $37.63.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) opened at 34.46 on Thursday. Fresenius Medical Care AG & Co. has a 52 week low of $31.28 and a 52 week high of $37.01. The stock has a 50-day moving average of $33.67 and a 200-day moving average of $34.02. The company has a market cap of $20.835 billion and a P/E ratio of 19.72.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its earnings data on Thursday, July 31st. The company reported $0.39 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.41 by $0.02. Analysts expect that Fresenius Medical Care AG & Co. will post $1.70 EPS for the current fiscal year.

A number of analysts have recently weighed in on FMS shares. Analysts at Zacks upgraded shares of Fresenius Medical Care AG & Co. from an “underperform” rating to a “neutral” rating in a research note on Monday, August 4th. They now have a $34.90 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Fresenius Medical Care AG & Co. from $33.00 to $34.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group downgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to an “underperform” rating in a research note on Monday, June 30th.

Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (NYSE:FMS).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.